Skip to main content

Table 2 Impact of baseline characteristics on patient prognosis in the training cohort (N = 203)

From: Prognostic value of ERBB4 expression in patients with triple negative breast cancer

 

Training N = 203 (%)

5-year disease relapse-free survival (%)

p-value

(Log-rank)

Age (median)

46.4 ± 10.2

  

 Range

23.5-74.1

 

0.633

  < 40 years

48 (23.6)

81.2

 

  ≥ 40 years

155 (76.4)

86.4

 

Histology

  

0.507

 IDCa

180 (88.7)

85.5

 

 Others

23 (11.3)

82.9

 

Stage

  

<0.001

 I

55 (27.1)

90.9

 

 IIA

94 (46.3)

91.5

 

 IIB

33 (16.3)

78.8

 

 IIIA

13 (6.4)

67.7

 

 IIIB

0 (0)

  

 IIIC

8 (3.9)

25.0

 

 Unknown

0 (0)

  

Nuclear grade

  

0.258

 1

2 (1.0)

50.0

 

 2

47 (23.2)

82.8

 

 3

145 (71.4)

86.9

 

 Unknown

9 (4.4)

77.8

 

Histologic grade

  

0.704

 1

3 (1.5)

100.0

 

 2

45 (22.2)

84.4

 

 3

144 (70.9)

86.0

 

 Unknown

11 (5.4)

72.7

 

EGFR (median: 7.0)

  

0.084

 Low

104 (51.2)

90.3

 

 High

99 (48.8)

79.8

 

ERBB2 (median: 9.0)

  

0.402

 Low

102 (50.2)

88.2

 

 High

101 (49.8)

82.1

 

ERBB3 (median: 7.2)

  

0.106

 Low

102 (50.2)

90.2

 

 High

101 (49.8)

80.1

 

ERBB4 (median: 1.3)

  

0.022

 Low

102 (50.2)

90.1

 

 High

101 (49.8)

80.2

 

ESR1 (median: 4.4)

  

0.689

 Low

102 (50.2)

84.2

 

 High

101 (49.8)

86.1

 

Adjuvant chemotherapy

  

0.001

 CMF1

86 (42.4)

90.7

 

 FAC2

58 (28.6)

86.0

 

 AC3

17 (8.4)

100.0

 

 AC –T4

41 (20.2)

65.9

 

 Unknown

1 (0.5)

100.0

 

Adjuvant RTx5

  

0.093

 Yes

130 (64.0)

83.0

 

 No

73 (36.0)

89.0

 
  1. aInvasive ductal carcinoma, 1Cyclophosphamide /Methotrexate/Fluorouracil, 2Fluorouracil/Adriamycin/Cyclophosphamide, 3Adriamycin/Cyclophosphamide, 4Taxane, 5Radiotherapy